MedRx Co., Ltd (4586.T)
JPY 84.0
(-3.45%)
JPY 84.0
(-3.45%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.05 Billion JPY | 46.75% |
| 2022 | 1.39 Billion JPY | -33.69% |
| 2021 | 2.1 Billion JPY | -8.22% |
| 2020 | 2.29 Billion JPY | 12.19% |
| 2019 | 2.04 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.92 Billion JPY | -6.37% |
| 2024 Q2 | 2.53 Billion JPY | 31.81% |
| 2023 Q3 | 2.26 Billion JPY | 30.67% |
| 2023 Q4 | 2.05 Billion JPY | -9.57% |
| 2023 Q1 | 1.23 Billion JPY | -11.54% |
| 2023 FY | 2.05 Billion JPY | 46.77% |
| 2023 Q2 | 1.73 Billion JPY | 40.41% |
| 2022 Q3 | 1.5 Billion JPY | 0.0% |
| 2022 FY | 1.39 Billion JPY | -33.69% |
| 2022 Q4 | 1.39 Billion JPY | -7.29% |
| 2021 FY | 2.1 Billion JPY | -8.22% |
| 2020 FY | 2.29 Billion JPY | 12.19% |
| 2019 FY | 2.04 Billion JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 36.57 Billion JPY | 94.389% |
| Takeda Pharmaceutical Company Limited | 15108.79 Billion JPY | 99.986% |
| Sumitomo Pharma Co., Ltd. | 907.5 Billion JPY | 99.774% |
| Shionogi & Co., Ltd. | 1416.91 Billion JPY | 99.855% |
| Wakamoto Pharmaceutical Co.,Ltd. | 15.42 Billion JPY | 86.694% |
| Nippon Shinyaku Co., Ltd. | 263.4 Billion JPY | 99.221% |
| Kaken Pharmaceutical Co., Ltd. | 171.62 Billion JPY | 98.804% |
| Eisai Co., Ltd. | 1393.79 Billion JPY | 99.853% |
| Morishita Jintan Co., Ltd. | 17.18 Billion JPY | 88.058% |
| Hisamitsu Pharmaceutical Co., Inc. | 328.77 Billion JPY | 99.376% |
| Mochida Pharmaceutical Co., Ltd. | 158.8 Billion JPY | 98.708% |
| Fuso Pharmaceutical Industries,Ltd. | 76.46 Billion JPY | 97.316% |
| Nippon Chemiphar Co., Ltd. | 49.54 Billion JPY | 95.859% |
| Tsumura & Co. | 428.25 Billion JPY | 99.521% |
| Kissei Pharmaceutical Co., Ltd. | 260.92 Billion JPY | 99.214% |
| Torii Pharmaceutical Co., Ltd. | 133.43 Billion JPY | 98.462% |
| Towa Pharmaceutical Co., Ltd. | 430.65 Billion JPY | 99.524% |
| Fuji Pharma Co., Ltd. | 85.33 Billion JPY | 97.595% |
| Zeria Pharmaceutical Co., Ltd. | 150.53 Billion JPY | 98.637% |
| KYORIN Holdings, Inc. | 177.67 Billion JPY | 98.845% |
| Taiko Pharmaceutical Co.,Ltd. | 15.04 Billion JPY | 86.362% |
| Daito Pharmaceutical Co.,Ltd. | 77.7 Billion JPY | 97.359% |
| SymBio Pharmaceuticals Limited | 15.35 Billion JPY | 86.634% |
| Mizuho Medy Co.,Ltd. | 18.94 Billion JPY | 89.171% |
| Solasia Pharma K.K. | 2.55 Billion JPY | 19.529% |
| Modalis Therapeutics Corporation | 2.02 Billion JPY | -1.287% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 93.31 Billion JPY | 97.801% |
| Sawai Group Holdings Co., Ltd. | 382.02 Billion JPY | 99.463% |
| Cyfuse Biomedical K.K. | 4.21 Billion JPY | 51.315% |
| Toho Holdings Co., Ltd. | 773.42 Billion JPY | 99.735% |
| Koa Shoji Holdings Co.,Ltd. | 32 Billion JPY | 93.588% |